Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Implant or insert
Patent
1993-10-21
1996-01-23
Page, Thurman K.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Implant or insert
424423, 424425, 424449, 424451, 424489, 424501, 424502, 5147723, 514810, 514811, 514812, 514813, 514953, 514955, 514963, 514965, A61F 202, A61K 970, A61K 948, A61K 950
Patent
active
054863627
ABSTRACT:
A drug delivery system useful in treating an individual for a drug dependence is described. One embodiment of the system is useful for aiding individuals in the cessation of smoking or chewing nicotine containing products is described. The delivery system includes a physical constraint modulation system (PCMS.TM.) containing lobeline. The drug delivery system is capable of delivering lobeline to an individual in a controlled, sustained release manner and providing long-term therapeutic levels of lobeline to the individual. The delivery of lobeline in such a manner reduces or eliminates the individual's smoking or chewing habit. The PCMS may be a biodegradable polymer containing the lobeline capable of subcutaneous or intramuscular injection or implantation into the individual or may be part of a transdermal patch containing lobeline. Also described are methods of using the drug delivery systems in treating other drug dependencies and kits containing the drug delivery systems.
REFERENCES:
patent: 3862946 (1975-01-01), Havera
patent: 3879555 (1975-04-01), Pachter et al.
patent: 3885027 (1975-05-01), Shaw et al.
patent: 3887699 (1975-06-01), Yolles
patent: 3906100 (1975-09-01), Havera
patent: 3947592 (1976-03-01), Grosz
patent: 3966940 (1976-06-01), Pachter
patent: 3976071 (1976-08-01), Sadek
patent: 3980766 (1976-09-01), Shaw et al.
patent: 4144228 (1979-03-01), Jones et al.
patent: 4145435 (1979-03-01), Szmuszkovicz
patent: 4177056 (1979-12-01), Mueller
patent: 4192827 (1980-03-01), Mueller
patent: 4248855 (1981-02-01), Blank et al.
patent: 4277582 (1981-07-01), Mueller et al.
patent: 4304591 (1981-12-01), Mueller et al.
patent: 4344431 (1982-08-01), Yolles
patent: 4361553 (1982-11-01), Loh et al.
patent: 4380550 (1983-04-01), Kleinlogel et al.
patent: 4444758 (1984-04-01), Scherschlicht et al.
patent: 4464378 (1984-08-01), Hussain
patent: 4592753 (1986-06-01), Panoz
patent: 4620977 (1986-11-01), Strahilevitz
patent: 4624665 (1986-11-01), Nuwayser
patent: 4632935 (1986-12-01), Kaplan
patent: 4678809 (1987-07-01), Phillips
patent: 4698342 (1987-10-01), Crosby
patent: 4719215 (1988-01-01), Goldberg
patent: 4745160 (1988-05-01), Churchill et al.
patent: 4749576 (1988-06-01), Lee
patent: 4767628 (1988-08-01), Hutchinson
patent: 4789726 (1988-12-01), Hutchinson
patent: 4822617 (1989-04-01), Panoz
patent: 4834973 (1989-05-01), Strahilevitz
patent: 4873086 (1989-10-01), Good et al.
patent: 4898734 (1990-02-01), Mathiowitz et al.
patent: 4908213 (1990-03-01), Govil et al.
patent: 4917676 (1990-04-01), Heiber et al.
patent: 4920989 (1990-05-01), Rose et al.
patent: 4935428 (1990-06-01), Lewis
patent: 4946853 (1990-08-01), Bannon et al.
patent: 4956391 (1990-09-01), Sapse
patent: 4963367 (1990-10-01), Ecanow
patent: 4994260 (1991-02-01), Kallstrand et al.
patent: 4996047 (1991-02-01), Kelleher et al.
patent: 5030216 (1991-07-01), Theeuwes et al.
patent: 5055478 (1991-10-01), Cooper et al.
Deasy, P. B., "Microencapsulation and related drug processes," Marcel Dekker, Inc., New York, pp. 223-224, Chapter 10.1.2: Narcotic antagonists, (1984).
Sharon, A. C., et al., "Development of drug delivery systems for use in treatment of narcotic addiction," Chemical Abstracts, vol. 96, No. 22:339-340, Abstract #192313k, & NIDA Res. Mongr. 28, 194-213 (1981).
Woodland, J. H. R., et al., "Long-acting delivery systems for narcotic antagonists," Journal of Medicinal Chemistry vol. 16, No. 8:897-901 (Aug. 1973).
Yolles, S., et al., "Long-acting delivery systems for narcotic antagonists II: release rates of naltrexone from poly(lactic acid) composits," Journal of Pharmaceutical Sciences, vol. 64, No. 2:348-349 (Feb. 1975).
Dorsey, J., "Control of the Tobacco Habit", Ann. Int. Medicine 10:628-631 (1936).
Hoffstaedt, E., "The Use of Lobeline in the Treatment of Smokers" The Medical Journal of Australia (Feb. 24, 1964).
Kalyuzhnyy, V. V., [English Translation of Russian Original], J. of Neural Psychiat. 68: 1864-1870 (1968).
London, S. J., "Clinical Evaluation of a New Lobeline Smoking Deterrent", Current Therapeutic Res. 5: 167-175 (1963).
Perlstein, I. B., Symposium on Recent Advances in the Medical Aspects of Smoking, The Matthew Publish. Co., N.Y. 40-45 (1964).
Prignot, J., "Pharmacological Approach to Smoking Cessation", Eur. Respir. J. 2: 550-560 (1969).
Swartz, H., "Clinical Evaluation of SMOKURB . . . ", Current Therapeutic Research 6: 290-296 (1964).
Scott, G. W. et al., "Buffered Lobeline as a Smoking Deterrent", Lancet, 58-59, Jan. 6, 1962.
Davison, G. et al., "Lobeline and Reduction of Cigarette Smoking" Psychological Reports 31: 443-446 (1972).
Merry, J. et al., "The Effect of Buffered Lobeline . . . ", Practitioner 190: 628-631 (1963).
Rapp, G. W. et al., "A Critical Evaluation of a Lobeline Based Smoking Deterrent", Amer. J. Med. Sci. 230: 9-14 (1955).
Rapp, G. W. et al., "Absorption and Utility of Lobeline As A Smoking Deterrent", Amer. J. Med. Sci. 237: 287-292 (1959).
Wright, I. et al., "Lobeline Sulfate: Its Pharmacology and Use . . . " J. Amer. Med. Assn.: 109, 649-654 (1937).
Schuster, C. R. et al., Chapter 8: "The Effects of d-Amphetamine, Meprobate, and Lobeline on the Cigarette Smoking Behavior" (1979).
Mullenix, P. et al., "The Effects of Nicotine and Lobeline on Spontaneous Behavior of Adult Male Rates", (Forsyth Research Institute, Boston, Mass., sponsored by DynaGen, Inc., Cambridge, Mass. (1990).
Reavill, C., et al., "High Affinity Binding of [3H] (-)-Nicotine to Rat Brain Membranes . . . ", Neuropharmacology 27: 235-241 (1988).
Sloan, J. W., et al., "The Comparative Binding Characteristics of Nicotinic Ligands . . . ", Pharmacol. Biochem. Behav. 30(1): 255-267 (1988).
Takagi et al., "Lobeline-containing Skin Patch to discourage tobacco smoking", 63-6 Pharmaceuticals, 1989 (Abstract).
Boyer Yvonne N.
Kitchell Judith P.
Muni Indu A.
Azpuru Carlos A.
DynaGen, Inc.
Page Thurman K.
LandOfFree
Controlled, sustained release delivery system for treating drug does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Controlled, sustained release delivery system for treating drug , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Controlled, sustained release delivery system for treating drug will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1503779